Table 3. Logistic regression model t predicting 6th month good- EULAR response to BCDT in RA patients.
| Variables | OR (95% CIs) |
| Current steroid therapy yes = 1 | 0.16 (0.03–0.78) |
| DAS, <3.7 = 1 | 0.88 (0.15–5.06) |
| HAQ, <1.5 = 1 | 2.24 (0.49–10.18) |
| Lymphocytes, <1875/ul = 1 | 10.74 (2.21–52.13) |
| ESR, <30mm/1st hr = 1 | 5.55 (0.93–29.00) |
| CRP, <5mg/l = 1 | 2.17 (0.21–21.95) |
| BAFF, <1011 pg/ml = 1 | 7.38 (1.24–43.76) |
| IL6, <15 pg/ml = 1 | 3.59 (0.78–16.40) |
| IgG-RF, >52.1U/ml = 1 | 8.37 (1.34–52.14) |
| IgA-RF, <37U/ml = 1 | 3.34 (0.68–16.45) |
| Anti-MCV, >36.5U/ml = 1 | 6.17 (0.63–60.07) |
| Hosmer and Lemeshow test | p = 0.95 |
The cut-off values for continuous variables related to the “good EULAR response to BCDT after 6th months FU” were obtained with ROC curves analysis. OR = odds ratio; 95%CI = 95% confidence interval; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; DAS = disease activity score; HAQ = Health Assessment Questionnaire; CCP = cyclic citrullinated protein; RF = rheumatoid factor; MCV = modified citrullinated vimentin. Boldface type indicates that P value is less than 0.05.